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Gram-negative bacteria-producing ex-
tended-spectrum b-lactamases (ESBLs) are
found to be truly multiresistant pathogens
causing severe clinical problems. In our
investigations, fifteen class C b-lactamases
with extended substrate spectra have been
reported in Gram-negative pathogens.
Because of the emergence and dissemina-
tion of these enzymes, we propose that
these enzymes be recognized as class C
ESBLs (cESBLs), although most of the
known ESBLs are class A and D b-
lactamases. To decrease the selective
pressure of antimicrobial drugs and min-
imize antimicrobial resistance, it is neces-
sary for health-care professionals to rec-
ognize the presence of emerging cESBLs
as a new and disturbing trend in antimi-
crobial resistance of Gram-negative path-
ogens. Because there is currently no drug
development against cESBL-producing
Gram-negative pathogens in progress and
large pharmaceutical companies have
largely withdrawn from research and
development of new antimicrobial drugs,
there is a tremendous need for the
development of new b-lactams (or b-
lactamase inhibitors) by focused coopera-
tion between academia and small phar-
maceutical companies, using the similar
structural mechanism (a potential thera-
peutic target) of the extended substrate
spectrum shown in most cESBLs.
The consensus view about antimicrobial
resistance is that severe clinical problems
arise from the emergence of antibiotic
resistance in Gram-negative pathogens
causing nosocomial infections, and from
the lack of new antimicrobial agents to
challenge the threat [1]. There are four
disturbing trends (extending substrate
spectra) in the increasing antimicrobial
resistance of Gram-negative pathogens
[1]: (i) class B b-lactamases (metallo-b-
lactamases) conferring resistance to almost
all b-lactam antibiotics [2]; (ii) a bifunc-
tional aminoglycoside-modifying enzyme
[3]; (iii) the evolution of a fluoroquinolone-
modifying enzyme from an aminoglyco-
side acetyltransferase [4]; and (iv) a new
plasmid-borne fluoroquinolone efflux de-
terminant [5]. These disturbing trends
indicate that options for the treatment of
health-care–associated Gram-negative in-
fections are perilously limited as the
organisms expand their ability to evade
existing antimicrobial agents [1,6]. Here
we wish to draw attention to a new
disturbing trend (the recently emerging
class C extended-spectrum b-lactamases
[ESBLs]), and to the antimicrobial drug
development for class C ESBLs. We
suggest also that the category of ESBLs
has to be expanded.
Epidemiology and
Characteristics of Class C ESBLs
Generally, ESBLs are defined as b-
lactamases able to hydrolyze the penicil-
lins, cephalosporins (first-, second-, and
third-generation), and monobactams (az-
treonam), but not the cephamycins or
carbapenems [7]. In other words, ESBLs
have an extended substrate spectrum as
compared with their parent types (non-
ESBLs). ESBLs can also be inhibited by b-
lactamase inhibitors such as clavulanic
acid. Most of the known ESBLs are class
A and D b-lactamases [7], but 15 class C
b-lactamases with extended substrate spec-
tra have been reported in Gram-negative
pathogens isolated from clinical specimens
of patients since the first description of
GC1 in 1995 (Table 1). Because of the
emergence and dissemination of these
enzymes, we propose that these enzymes
are recognized as class C ESBLs. Then
class A, C, and D ESBLs would be
designated aESBLs, cESBLs, and dESBLs,
respectively.
The cESBLs were first defined as
follows: i) extended specificity class C b-
lactamase for GC1 in 1995 [8]; ii)
extended-spectrum AmpC-type b-lacta-
mase for MHN-7.6 in 1998 [9]; iii)
extended-spectrum class C b-lactamase
for GC1 in 1999 [10]; and iv) extended-
spectrum AmpC b-lactamase (ESAC) for
CHE in 2001 [11]. Class C b-lactamase
was designated AmpC b-lactamase [12].
Therefore, extended-spectrum class C
(AmpC) b-lactamase can be designated
class C extended-spectrum b-lactamase
(cESBL). Most cESBL (13 of 15 natural
cESBLs produced by Gram-negative path-
ogens isolated from clinical specimens of
patients: SMSA, CHE, Ear2, AmpC
D,
HD, EC14, EC15, EC17, EC19, CMY-
19, BER, 520R, and KL) have extended
their substrate specificity to third- and
fourth-generationcephalosporins(Table1).
Some cESBLs (CMY-10 and BER) can
hydrolyse carbapenems (imipenem or
meropenem), which have the same sub-
strate specificity as that of aESBLs such as
GES-5 [13]. A cESBL (AmpC
D) can be
inhibited also by b-lactamase inhibitors
(tazobactam and sulbactam) just like
aESBLs and dESBLs. The hydrolytic
efficiency (kcat/Km) of cESBLs for ceftazi-
dime and cefotaxime was higher than or
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M-15 [15], typical aESBLs. Some b-
lactamase investigators [16–19] have tried
to distinguish the difference between
ESACs and cESBLs, but, except for
cephamycins (cefoxitin and cefotetan),
hydrolysis patterns do not differ between
ESACs and cESBLs. Furthermore, ESBL-
producing clinical isolates were also resis-
tant to cephamycins by reduced outer
membrane permeability [20]. In 2003,
Hanson warned that if we have failed to
distinguish between ESBL and plasmid-
encoded class C b-lactamase (non-cESBL)
producers, we would run the risk of the
emergence of cESBLs [21]. Unfortunately,
cESBLs have already emerged, and the
phenotypic susceptibility testing to distin-
guish between aESBLs (or dESBLs) and
emerging cESBLs is very difficult.
Treatment for cESBL-Producing
Gram-Negative Pathogens
The Infectious Diseases Society of
America identified six top-priority danger-
ous pathogens (e.g., ESBL-producing En-
terobacteriaceae, Acinetobacter baumannii, Pseu-
domonas aeruginosa, vancomycin-resistant
Enterococcus faecium, methicillin-resistant
Staphylococcus aureus, and Aspergillus species)
for which there are few or no drugs in late-
stage development, further limiting the
choice of an appropriate and safe treat-
ment for these infections [22,23]. Three of
six dangerous pathogens are antibiotic-
resistant Gram-negative bacteria. Recent-
ly, antimicrobial drugs against ESBL-
producing Gram-negative pathogens ac-
counted for about 15% (2 of 13) of all
antimicrobial drugs undergoing develop-
ment in phase II or later clinical studies
[22]. There are no drug developments
against cESBL-producing Gram-negative
pathogens.
Rubinstein and Zhanel, hospital physi-
cians, have stated that physicians are
increasingly forced to use the carbapenems
and fluoroquinolones (ciprofloxacin or
levofloxacin) as first-line therapy for
ESBL-producing Gram-negative patho-
gens, but the situation will become even
more severe as ESBL-producing organ-
isms increasingly become concomitantly
Table 1. Epidemiology and characteristics of class C extended-spectrum b-lactamases (cESBLs)
Enzyme*
Extended Substrate
Spectrum
{ (Parent
Enzyme)
Country of Origin
(Clinical Isolation) Bacterial Species
Region (Mutation Site)
{ Causing
Extended Substrate Spectrum Reference
GC1 CAZ, ATM (P99) Japan, 1992 E. cloacae GC1 V-loop (the insertion of Ala-Val-Arg after
position 210)
[8,10]
SRT-1 CAZ, CTX, CMX (SST-1) Japan, 1985 S. marcescens GN16694 V-loop (Glu213 R Lys) [28]
SMSA (Ser
R) CAZ, FEP, FPI (SLS73, Ser
S) France, 2000 S. marcescens SMSA V-loop (Ser220 R Tyr) [29]
CHE CTX, FEP, FPI (P99) France, 1998 E. cloacae CHE R2-loop (a six-amino-acid-deletion,
SKVALA at positions 289–294)
[11]
Ear2 CTX, FEP (Ear1) France, 2001 E. aerogenes Ear2 R2-loop (Leu293 R Pro) [30]
AmpC
D CAZ, FEP, FPI, inhibitor-
sensitive (AmpC
R,
revertant)
Japan, 1994 E. coli HKY28 R2-loop (a tripeptide deletion, GSD, at
positions 286–288)
[31]
HD CAZ, FEP, FPI (S3) France, 2001 S. marcescens HD R2-loop (a four-amino-acid-deletion,
MNGT, at positions 293–296)
[16]
EC14 CAZ, FEP (EC1) France, 2002–2005 E. coli EC14 R2-loop (Val298 R Leu) [17]
EC15 CAZ, FEP (EC1) France, 2002–2005 E. coli EC15 R2-loop (His296 R Pro) [17]
EC17 CAZ, FEP (EC1) France, 2002–2005 E. coli EC17 R2-loop (His296 R Pro) [17]
EC19 CAZ, FEP (EC1) France, 2002–2005 E. coli EC19 R2-loop (His296 R Pro) [17]
CMY-19 CAZ, FEP, FPI (CMY-9) Japan, 1996 K. pneuminiae HKY327 R2-loop (Ile292 R Ser) [32]
CMY-10 CAZ, IMP (P99) Korea, 1999 E. aerogenes K9911729 R2-loop (a tripeptide deletion, PPA, at
positions 303–305)
[24]
BER CAZ, CTX, CRO, FEP, IMP
(EC2)
France, 2006 E. coli BER R2-loop (the insertion of Ala-Ala after
position 293)
[18]
MHN-7.6 CAZ, FEP, FPI (MHN) In vitro mutation E. coli K12 strain MI1443 R2-loop (Val298 R Glu) [9]
AmpC1 CAZ, FEP (P99) In vitro mutation E. coli JM83 R2-loop (Leu293 R Pro) [33]
Seven mutant
enzymes
CAZ, FEP (CMY-2) In vitro mutation E. coli DH5aE R2-loop (Val291 R Ala[Gly]; Ala292 R Pro;
Leu293 R Pro; Ala294 R Glu; Leu296 R Pro;
Ala298 R Val)
[34]
520R CAZ, FPI (S3) In vitro mutation E. coli DH5a H-2 helix (Thr64 R Ile) [35]
KL CAZ, FEP, FPI (S4) France, 2001 E. coli KL H-11 helix (Val350 R Phe) [19]
*Crystallographic structures from distinct GC1 (Protein Data Bank [PDB] code 1GCE) and CMY-10 (PDB code 1ZKJ) only have been resolved. Ser
R is the in vitro site-
directed mutant of SLS73 (Ser
S). All enzymes except plasmid-encoded CMY-10 and CMY-19 are chromosomal cESBLs. All enzymes except several enzymes (Ser
R,S e r
S,
AmpC
R, AmpC1 [in vitro Leu-293-Pro mutant of P99], seven mutants of CMY-2, MHN-7.6, and 520R) are the naturally (clinically) occurring cESBLs produced by clinical
isolates. AmpC
D is the only inhibitor-(tazobactam and sulbactam)sensitive cESBL.
{CAZ, ceftazidime; CTX, cefotaxime; CMX, cefmenoxime; CRO, ceftriaxone; FEP, cefepime; FPI, cefpirome; IMP, imipenem; ATM, aztreonam. Each cESBL has extended its
substrate specificity in comparison with each parent enzyme (non-cESBL).
{V-loop lays from residues 189 to 226 in P99 b-lactamase. R2-loop lays from residues 289 to 307 in CMY-10 b-lactamase. The position of the N-terminal amino acid of the
mature enzyme (without the respective signal peptide) is designated as position 1 of the amino acid sequence. The tripeptide deletion of AmpC
D is located just before
the R2-loop but causes a structural change in the R2-loop. Glu213 R Lys, the substitution of glutamic acid (Glu) by lysine (Lys) at residue 213.
doi:10.1371/journal.ppat.1000221.t001
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However, we recently found that the
CMY-10 cESBL had higher imipenem-
hydrolysing activity than OXA-23, a class
D carbapenemase [24]. Because this
extended substrate spectrum of cESBLs
can threaten the management of infections
by Gram-negative pathogens producing
these enzymes, new antimicrobial drugs
against cESBL-producing Gram-negative
pathogens are urgently needed. To devel-
op these antimicrobial drugs, it is neces-
sary to know the operative mechanism of
cESBLs to extend their substrate spec-
trum.
Antimicrobial Drug
Development for cESBLs
How do the cESBLs extend the sub-
strate spectrum? The crystallographic
structures can answer this question. Until
now, there are two only resolved crystal-
lographic structures of cESBLs: (i) GC1
(Protein Data Bank [PDB] code, 1GCE)
[10]; and (ii) CMY-10 (PDB code, 1ZKJ)
[24]. Kinetic data and the crystal structure
of GC1 showed that GC1 was a natural
(clinically isolated) cESBL due to the
flexibility of the V-loop caused by the
insertion of Ala-Val-Arg after position 210
[8,10]. As shown in the Table 1, this
structural characteristic of chromosomal
GC1 provides insights into the molecular
basis of extended substrate spectrum
shown in only three cESBLs (GC1, SRT-
1, and SMSA). But our kinetic data and
crystal structure [24] of a plasmid-encoded
cESBL (i.e., CMY-10) reveal the operative
molecular strategy of most cESBLs (73%,
11 of the total 15) to extend their substrate
spectrum. The region responsible for the
extended substrate spectrum is the R2-
loop (amino acid residues 289–307;
Figure 1) [24]. Our sequence alignment
of natural (clinically isolated) cESBLs
shows that the R2-loop includes all regions
responsible for the extended substrate
spectrum in most (11 of the total 15)
cESBLs: V-loop in three cESBLs; H-2
helix in a 520R cESBL (not natural); H-11
helix in a KL cESBL (Table 1 and
Figure 1). These natural (from clinical
isolates) mutations in the R2-loop can
change the architecture of the active site in
cESBLs, thereby affecting their hydrolys-
ing activity. Owing to a three-amino-acid
deletion (amino acid residues 303–305) in
CMY-10, for example, the R2-loop in the
R2 active site (i.e., the region that
accommodates the R2 side-chain at C3
of the b-lactam nucleus in oxyimino-
cephalosporins) displays noticeable struc-
tural alterations: the significant widening
of the R2 active site. Therefore, the bulky
R2 side-chain of oxyimino-cephalosporins
could fit snugly into the significant widen-
ing of the R2 active site in this way. In
view of no drug developments against
cESBL-producing Gram-negative patho-
gens, new b-lactams or b-lactamase inhib-
itors need to be developed by the struc-
ture-based drug design (SBDD) method
[25] using a similar mechanism (the
significant widening of the R2 active site)
of the extended substrate spectrum shown
in most cESBLs. Clinically available b-
lactamase inhibitors co-administered with
less effective b-lactams are effective against
class A b-lactamases, but show little or no
activity against class C b-lactamases.
Therefore, class C b-lactamases are an
excellent drug target with accurate struc-
tural information [25]. Since Gram-nega-
tive pathogens producing cESBLs are
increasing in emergence and spreading
among organisms causing nosocomial
infections (Table 1), there is an urgent
need to develop an inhibitor of cESBLs or
to discover new antimicrobial drugs for
Figure 1. Ribbon diagram of crystallographic structure of CMY-10 (a cESBL). The image was rendered with PyMOL, available on the
Internet (http://sourceforge.net/projects/pymol). The R2-loop is represented as red, while the V-loop, H-2 helix, and H-11 helix are depicted in violet,
blue, and cyan, respectively. The R1 active site (central upper region) is surrounded by the V-loop and the R2 active site (central lower region) by the
R2-loop and H-11 helix. The nucleophile (Ser65), attacking the carbonyl carbon of b-lactam ring, is present in the H-2 helix.
doi:10.1371/journal.ppat.1000221.g001
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Although large pharmaceutical companies
have largely withdrawn from research and
development of new antimicrobial drugs, a
few academic research groups (e.g., our
group, or Shoichet’s laboratory [26]) and
small pharmaceutical companies (e.g.,
Novexel [27], which has been spun out
of Aventis and Anacor that has formed a
worldwide strategic alliance with GlaxoS-
mithKline) are seeking these new b-
lactamase inhibitors. The discovery of
some lead compounds against CMY-10
b-lactamases by SBDD is in progress, by
focused cooperation between academia
and small pharmaceutical companies.
Conclusion
Since the emergence and dissemination
of fifteen class C extended-spectrum b-
lactamases (ESBLs) produced by Gram-
negative pathogens isolated from clinical
specimens of patients, the category of
ESBLs has broadened to include class C
b-lactamases with extended substrate spec-
trum. We propose that these enzymes be
recognized as class C ESBLs (cESBLs).
Phenotypic susceptibility testing to distin-
guish the difference between organisms
producing general ESBLs (e.g., aESBLs or
dESBLs) or emerging cESBLs is very
challenging. The difficulty in type identi-
fication of ESBLs hinders hospital infec-
tion control and the ability of the physi-
cian to prescribe the most appropriate
antibiotic, thus increasing the selective
pressure and generating antibiotic resis-
tance. It is necessary for health-care
professionals to recognize the presence of
emerging cESBLs as a new and disturbing
trend in antimicrobial resistance of Gram-
negative pathogens. Furthermore, there is
currently no drug development in progress
against cESBL-producing Gram-negative
pathogens. Therefore, there is a tremen-
dous need for the development of new b-
lactams or b-lactamase inhibitors by the
structure-based drug-design method using
the similar structural mechanism (the
significant widening of the R2 active site)
of the extended substrate spectrum shown
in most cESBLs.
Accession Number
The Protein Data Bank (PDB, http://
www.rcsb.org/pdb/) accession code for
the protein discussed in this paper is
CMY-10 (1ZKJ, [24]).
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